The US Food and Drug Administration (FDA) has approved Tekturna HCT tablets from Novartis as an alternative initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals.

Tekturna HCT is a single-pill combination of Tekturna (aliskiren) and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly used high blood pressure medications.

The FDA granted approval based on clinical trials involving more than 2,700 patients, which showed that the combination of Tekturna and HCTZ offered greater blood pressure reductions than either drug alone.

Western Pennsylvania Hospital cardiologist and professor of medicine at Temple University Dr Alan Gradman said that this approval gives doctors the opportunity to aggressively treat their patients with a single-pill combination.

“This results in more significant blood pressure reductions, compared to taking either drug alone,” Gradman said.